MRRS adds "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – high blood glucose levels – that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Table of Contents
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 46
3.4.1 Pioglitazone 46
3.4.2 Duvie (lobeglitazone) - Chong Kun Dang 48
3.5 GLP-1 Receptor Agonists 48
3.5.1 Byetta (exenatide) - Eli Lilly 48
3.5.2 Bydureon (exenatide) - AstraZeneca 49
3.5.3 Victoza (liraglutide) - Novo Nordisk 50
3.5.4 Lyxumia (lixisenatide) - Sanofi 52
3.5.5 Tanzeum (albiglutide) - GlaxoSmithKline 53
3.6 DPP-4 Inhibitors 54
3.6.1 Januvia (sitagliptin) - Merck 54
3.6.2 Galvus (vildagliptin) - Novartis 55
3.6.3 Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca 57
3.6.4 Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca 58
3.6.5 Zemiglo (gemigliptin) - LG Life Sciences 59
3.6.6 Suganon (evogliptin) - Dong-A ST 59
3.6.7 Gadret (anagliptin) - JW Pharmaceutical 60
3.6.8 Nesina (alogliptin) - Takeda 61
3.6.9 Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma 61
3.7 SGLT-2 Inhibitors 62
3.7.1 Forxiga (dapagliflozin) - AstraZeneca 62
3.7.2 Invokana (canagliflozin) - Janssen 63
3.7.3 Jardiance (empagliflozin) - Boehringer Ingelheim 64
3.7.4 Suglat (ipragliflozin) - Astellas 65
3.8 Insulin Therapies 66
3.8.1 Lantus (insulin glargine) - Sanofi 66
3.8.2 Levemir (insulin detemir) - Novo Nordisk 67
3.8.3 Tresiba (insulin degludec) - Novo Nordisk 67
3.8.4 Toujeo (insulin glargine) - Sanofi 68
3.9 Comparative Efficacy and Safety of Marketed Products 69
4 Pipeline 72......

List of Tables and Figures 
Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy 26
Table 2: T2DM Therapeutics, Global, All Pipeline Products, Discovery Stage, March 2016 138
Table 3: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Stage, March 2016 141
Table 4: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Stage, March 2016 149
Table 5: T2DM Therapeutics, Global, All Pipeline Products, Phase I, March 2016 149
Table 6: T2DM Therapeutics, Global, All Pipeline Products, Phase II, March 2016 151
Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase III, March 2016 153
Table 8: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Stage, March 2016 154
Table 9: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2015-2022 155
Table 10: T2DM Therapeutics Market, South Korea, Market Forecast, 2015-2022 155
Table 11: T2DM Therapeutics Market, Singapore, Market Forecast, 2015-2022 156
Table 12: T2DM Therapeutics Market, Taiwan, Market Forecast, 2015-2022 156.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/type-2-diabetes-mellitus-therapeutics-in-south-east-asia-markets-to-2022-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/